SRNE - Sorrento says first patient treated in early-stage Amyloidosis study

Sorrento Therapeutics (SRNE) announces that the first patient has been treated in its Phase 1b Amyloid Light Chain ((AL)) Amyloidosis study of STI-6129, an antibody-drug conjugate ((ADC)) which uses STI-5171, a fully human monoclonal antibody (mAb) from Sorrento’s G-MAB library.The study is being conducted as a multicenter, open-label, dose-escalation clinical trial in patients with advanced relapsed and/or refractory systemic amyloid light chain ((AL)) amyloidosis with a primary objective to identify a Phase 2 dose for STI-6129 based on its safety, preliminary efficacy and pharmacokinetic profile.The company said that it will further evaluate the safety and efficacy of STI-6129 in a refractory or relapsing multiple myeloma clinical trial, which is expected to start soon.

For further details see:

Sorrento says first patient treated in early-stage Amyloidosis study